trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Rosuvastatin treatment increases mean HbA1c levels in patients compared to placebo.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Rosuvastatin treatment increases mean HbA1c levels in patients compared to placebo?

Yes. Rosuvastatin and other high-intensity statins are associated with an increased risk of new-onset diabetes and worsening glycemic measures such as HbA1c compared to placebo or non-use.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked

The analysis

Multiple papers, including reviews and clinical studies, consistently indicate that high-intensity statins like rosuvastatin increase the risk of new-onset diabetes and negatively impact glycemic control, supporting the claim.

Evidence for · 4
Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years
2020
This retrospective study demonstrates that statin use is significantly associated with new-onset type 2 diabetes mellitus.
Get citation
Tangelloju, S., Little, B. B., Esterhay, R. J., Brock, G., & LaJoie, S. (2020). Statins are associated with new onset type 2 diabetes mellitus (T2DM) in Medicare patients ≥65 years. doi.org. https://doi.org/10.1002/dmrr.3310

See more details
More for · 3
Statin Induced New-onset Diabetes Mellitus - A Narrative Review.
2026
This review highlights that high-intensity statins like rosuvastatin carry a greater risk of new-onset diabetes mellitus.
Get citation
JK, M. & SK, B. (2026). Statin Induced New-onset Diabetes Mellitus - A Narrative Review.. doi.org. https://doi.org/10.55729/2000-9666.1563

Effects of statins on glycemic control and cardiovascular events in patients with new-onset type 2 diabetes: a retrospective cohort study.
2026
This cohort study finds that statin initiation leads to worse short-term glycemic improvement and higher rates of diabetes therapy intensification.
Get citation
Y, R., L, J., J, R., Y, Z., L, P., B, Y., X, R., H, D., S, W., & X, L. (2026). Effects of statins on glycemic control and cardiovascular events in patients with new-onset type 2 diabetes: a retrospective cohort study.. doi.org. https://doi.org/10.3389/fendo.2026.1921249

Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects.
2026
This review identifies rosuvastatin and other high-intensity statins as having pronounced diabetogenic properties affecting glucose metabolism.
Get citation
AN, A. & M, K. (2026). Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects.. doi.org. https://doi.org/10.1002/edm2.70305

What does the evidence say?

Multiple papers, including reviews and clinical studies, consistently indicate that high-intensity statins like rosuvastatin increase the risk of new-onset diabetes and negatively impact glycemic control, supporting the claim.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work